These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37317775)

  • 1. Scleromyxedema: A rare case report with dermoscopic findings.
    Prakashey A; Mehta H; H Bharti A; Agharia R
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):96-98. PubMed ID: 37317775
    [No Abstract]   [Full Text] [Related]  

  • 2. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
    Topf S; Simon M; Schell H; Lüftl M
    Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
    Wang SS; Chen QY; Xiang LH
    Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleromyxedema.
    Hummers LK
    Curr Opin Rheumatol; 2014 Nov; 26(6):658-62. PubMed ID: 25215418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema.
    Binitha MP; Nandakumar G; Thomas D
    Indian J Dermatol Venereol Leprol; 2008; 74(3):248-50. PubMed ID: 18583794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An unusual presentation of scleromyxedema as inflammatory myopathy.
    Vysakha KV; Poyuran R; Nair SS; Nair M
    Acta Myol; 2019 Mar; 38(1):13-16. PubMed ID: 31309176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare.
    Rongioletti F; Cozzani E; Parodi A
    J Cutan Pathol; 2010 Oct; 37(10):1084-7. PubMed ID: 19638067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scleromyxedema.
    Yang Y; Chen H; Zhang W; Sun JF
    Indian J Dermatol Venereol Leprol; 2016; 82(6):738-739. PubMed ID: 26858056
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
    Brunet-Possenti F; Hermine O; Marinho E; Crickx B; Descamps V
    J Am Acad Dermatol; 2013 Aug; 69(2):319-20. PubMed ID: 23866873
    [No Abstract]   [Full Text] [Related]  

  • 10. Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.
    Rabee H; Tayem L; Gharbeyah M; Abugaber D
    BMC Dermatol; 2020 Dec; 20(1):18. PubMed ID: 33276772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scleromyxedema.
    Bogner RR; Wetter DA; Dingli D
    Intern Med; 2014; 53(21):2561-2. PubMed ID: 25366027
    [No Abstract]   [Full Text] [Related]  

  • 12. [Scleromyxedema with neurological symptoms: successful treatment with immunoglobulins].
    Manríquez J; Berroeta-Mauriziano D; Andino-Navarrete R; Vera-Kellet C
    Med Clin (Barc); 2015 Jan; 144(1):47-8. PubMed ID: 24656121
    [No Abstract]   [Full Text] [Related]  

  • 13. Scleromyxedema vs scleredema: a diagnostic challenge.
    Conde Fernandes I; Sanches M; Velho G; Lobo I; Alves R; Selores M
    Eur J Dermatol; 2011; 21(5):822-3. PubMed ID: 21771713
    [No Abstract]   [Full Text] [Related]  

  • 14. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
    Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
    Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema.
    Khandkar C; Vaidya K; Penglase R; Cai K; Shin JS; Hunyor I; Keech A; McGill N
    Intern Med J; 2020 Jan; 50(1):127-128. PubMed ID: 31943623
    [No Abstract]   [Full Text] [Related]  

  • 16. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
    Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
    Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
    Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
    J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report.
    Arginelli F; Paganelli A; Rongioletti F; Pellacani G; Conti A
    Dermatol Ther; 2018 Mar; 31(2):e12583. PubMed ID: 29214719
    [No Abstract]   [Full Text] [Related]  

  • 19. Scleromyxedema.
    Chatterjee S; Fernandez AP
    N Engl J Med; 2023 Nov; 389(21):1992. PubMed ID: 37991858
    [No Abstract]   [Full Text] [Related]  

  • 20. Scleromyxedema.
    Liu CH; Tsai YY; Tien YC
    Rheumatology (Oxford); 2022 Jul; 61(7):e201-e200. PubMed ID: 34554227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.